Drug Profile
Research programme: mRNA therapeutics - Arcturus Therapeutics/CureVac
Latest Information Update: 17 Apr 2020
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics; CureVac
- Class RNA
- Mechanism of Action Protein biosynthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 11 Feb 2019 Arcturus Therapeutics terminates its licence for ARCT 810
- 31 Jul 2018 Preclinical trials in Inborn urea cycle disorders (ornithine transcarbamylase deficiency) in Germany (Parenteral) (CureVac pipeline, July 2018)
- 31 Jul 2018 Preclinical trials in Inborn urea cycle disorders (ornithine transcarbamylase deficiency) in USA (Parenteral) (CureVac pipeline, July 2018)